• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 DNA 的纳米卡尺快速测定 EGFR 突变。

Rapid determination of the presence of EGFR mutations with DNA-based nanocalipers.

机构信息

Department of Biomedical Engineering, School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

出版信息

Nanoscale. 2023 Aug 25;15(33):13834-13841. doi: 10.1039/d3nr02665e.

DOI:10.1039/d3nr02665e
PMID:37580989
Abstract

Selecting 1st-line treatment for lung cancer is currently a binary choice, either chemotherapy or targeted medicine, depending on whether EGFR mutations exist. Next-generation sequencing is fully capable of accurately identifying EGFR mutations and guiding the usage of tyrosine kinase inhibitors, but it is highly expensive. Moreover, as the sequencing is not helpful for patients with wild-type EGFR, the long wait for sequencing may delay the chemotherapy and correspondingly increase the risks of cancer progression. To address this issue, a new method for rapidly determining the presence of EGFR mutations is developed in this study. A series of DNA origami-engineered nanocalipers are designed and constructed to determine the EGFR spatial distribution of either mutated EGFR or wild-type EGFR lung cancer cells. The experimental results on cancer cell lines and 9 clinical tissue samples show that compared with wild-type EGFR cells, mutated EGFR cells have narrower EGFR spacing. Hence, the DNA nanocalipers are demonstrated to be capable of determining the presence of EGFR mutations and shrinking the detection period from weeks to hours, compared with sequencing. For determining EGFR mutation status in 9 clinical samples, DNA nanocalipers show 100% consistency with next-generation sequencing.

摘要

选择肺癌一线治疗方案目前是一个二元选择,要么化疗,要么靶向药物,取决于是否存在 EGFR 突变。下一代测序完全能够准确识别 EGFR 突变并指导酪氨酸激酶抑制剂的使用,但费用非常高。此外,由于测序对 EGFR 野生型患者没有帮助,因此长时间等待测序可能会延迟化疗,并相应增加癌症进展的风险。针对这一问题,本研究开发了一种快速确定 EGFR 突变存在的新方法。设计并构建了一系列 DNA 折纸工程纳米卡尺,以确定突变型 EGFR 或野生型 EGFR 肺癌细胞中 EGFR 的空间分布。在癌细胞系和 9 个临床组织样本上的实验结果表明,与野生型 EGFR 细胞相比,突变型 EGFR 细胞的 EGFR 间距更窄。因此,与测序相比,DNA 纳米卡尺能够确定 EGFR 突变的存在,并将检测周期从几周缩短到几小时。对于 9 个临床样本中 EGFR 突变状态的确定,DNA 纳米卡尺与下一代测序具有 100%的一致性。

相似文献

1
Rapid determination of the presence of EGFR mutations with DNA-based nanocalipers.基于 DNA 的纳米卡尺快速测定 EGFR 突变。
Nanoscale. 2023 Aug 25;15(33):13834-13841. doi: 10.1039/d3nr02665e.
2
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.基于皮升液滴数字聚合酶链反应的游离血浆DNA分析,以评估肺腺癌中对酪氨酸激酶抑制剂产生耐药性的表皮生长因子受体突变
Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.
3
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.应用基于扩增子的靶向测序与分子条形码系统检测未经治疗的肺腺癌患者中罕见的次要 EGFR 突变。
BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.
4
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).靶向测序可识别出导致对表皮生长因子受体酪氨酸激酶抑制剂产生原发性耐药的基因改变(韩国肺癌联盟)。
Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.
5
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.检测和比较肽核酸介导的实时聚合酶链反应夹心法和直接基因测序在非小细胞肺癌患者表皮生长因子受体突变中的应用。
Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17.
6
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.KEAP1/NFE2L2/CUL3 突变对 EGFR 突变型非小细胞肺癌患者接受 EGFR 酪氨酸激酶抑制剂治疗反应持续时间的影响。
Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.
7
Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.在非吸烟肺腺癌患者中,比较靶向二代测序与传统测序在预测表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗反应性方面的差异。
Lung Cancer. 2014 Aug;85(2):161-7. doi: 10.1016/j.lungcan.2014.04.009. Epub 2014 Apr 29.
8
Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.组织和循环肿瘤 DNA 的下一代测序:在一组晚期非小细胞肺癌患者中对 EGFR 靶向治疗的耐药机制。
Cancer Med. 2021 Jul;10(14):4697-4709. doi: 10.1002/cam4.3948. Epub 2021 Jun 25.
9
Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).肺癌表皮生长因子受体(EGFR)第18至21外显子的下一代测序可对小的常规样本(细胞学和活检样本)进行有效的分子诊断。
PLoS One. 2013 Dec 23;8(12):e83607. doi: 10.1371/journal.pone.0083607. eCollection 2013.
10
Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.液体活检靶向捕获测序分析在提高非小细胞肺癌酪氨酸激酶抑制剂精准治疗中的应用。
BMJ Open Respir Res. 2022 Jan;9(1). doi: 10.1136/bmjresp-2021-001154.

引用本文的文献

1
DNA-modulated dimerization and oligomerization of cell membrane receptors.DNA 调控的细胞膜受体二聚化和寡聚化。
Chem Commun (Camb). 2024 Sep 16;60(75):10265-10279. doi: 10.1039/d4cc03077j.